Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064367 | 0.80 | HPGD (0.33) | HPGDDGAT1GAAEPHX1CTSK | |
| SCHEMBL5568399 | 0.78 | HPGD (0.32) | HPGDDGAT1GAAEPHX1CTSK | |
| SCHEMBL136090 | 0.77 | HPGD (0.31) | HPGDDGAT1GAA | |
| SCHEMBL5421441 | 0.77 | HPGD (0.31) | HPGDDGAT1GAA | |
| SCHEMBL14896297 | 0.76 | DGAT1 (0.32) | DGAT1CTSK | |
| SCHEMBL4011681 | 0.75 | HPGD (0.30) | HPGD | |
| SCHEMBL2785917 | 0.74 | DGAT1 (0.31) | DGAT1CTSK | |
| SCHEMBL5881754 | 0.74 | CTSK (0.31) | CTSK | |
| SCHEMBL1296518 | 0.74 | HPGD (0.33) | HPGDEPHX1CTSK | |
| SCHEMBL2877401 | 0.74 | DGAT1 (0.36) | DGAT1GAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260227-A1 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | claimed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | claimed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| EP-2892912-B1 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20170260227-A1 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9593074-B2 | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof | REATA PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2892912-A1 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | Reata Pharmaceuticals, Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20140100227-A1 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| WO-2014040060-A1 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | disclosed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100227-A1 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | ALOX12, ALOX15, ALOX15B | HPGD 222/4885DGAT1 85/4885GAA 3594/4885 |
| US-20170260227-A1 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF | ALOX12, ALOX15, ALOX15B | HPGD 222/4885DGAT1 85/4885GAA 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.